Open Payments

Rady Childrens Hospital - San Diego

Type
Teaching hospital
Where
San Diego, CA
Medicare CCN
053303
Received
$188,309 in 84 records, 2020 ($46,857 general, $141,452 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment14$46,857
2020Research payment70$141,452

By company

CompanyRecordsAmountYears
Soleno Therapeutics, Inc.2$58,7942020
PFIZER INC.6$57,1502020
Alexion Pharmaceuticals, Inc.1$20,0002020
DERMIRA, INC.1$15,2502020
Boehringer Ingelheim Pharma GmbH & Co.KG7$13,0802020
Nabriva Therapeutics, plc5$10,4652020
Merck Sharp & Dohme LLC28$3,5912020
Masimo Corporation3$3,1902020
Linvatec Corporation1$2,0222020
Cochlear Americas2$1,7502020
Phadia US Inc.5$9002020
Eli Lilly and Company2$5662020
Incyte Corporation16$4032020
KARL STORZ Endoscopy-America1$3482020
Hikma Pharmaceuticals USA1$3182020
Insulet Corporation1$3002020
Covidien LP1$1672020
Vero Biotech Inc.1$112020

By nature of payment

NatureRecordsAmount
Research payment70$141,452
Space rental or facility fees (teaching hospital only)4$25,250
Consulting Fee1$15,250
Education3$3,190
Grant2$2,190
Gift1$348
Food and Beverage2$329
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$300

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Linvatec Corporation$2,022GrantIn-kind items and servicesMICROFREE Device, ORTHOPEDIC SURGERY2020
2020-12-31Boehringer Ingelheim Pharma GmbH & Co.KG$1,349Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-12-31Masimo Corporation$897EducationIn-kind items and servicesSedLine Device, Devices2020
2020-12-31Masimo Corporation$182EducationIn-kind items and servicesrainbow Acoustic Monitoring Device, Devices2020
2020-12-16Phadia US Inc.$150Research paymentIn-kind items and servicesImmunoCAP Device, AllergyCABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population2020
2020-12-07PFIZER INC.$13,895Research paymentIn-kind items and servicesZAVICEFTA NEONATAL SEPSIS TRIAL2020
2020-11-21Masimo Corporation$2,109EducationIn-kind items and servicesrainbow Acoustic Monitoring Device, Devices2020
2020-11-19Vero Biotech Inc.$11Food and BeverageIn-kind items and servicesGenosyl Drug, Respiratory Therapy2020
2020-11-04Alexion Pharmaceuticals, Inc.$20,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2020
2020-10-16Nabriva Therapeutics, plc$2,275Research paymentCash or cash equivalentA Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I2020
2020-09-30Soleno Therapeutics, Inc.$34,894Research paymentCash or cash equivalentDiazoxide Choline Controlled Release (DCCR) Drug, Prader-Willi SyndromeA Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients w2020
2020-09-30Soleno Therapeutics, Inc.$23,899Research paymentCash or cash equivalentDiazoxide Choline Controlled Release (DCCR) Drug, Prader-Willi SyndromeAn Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with 2020
2020-09-24Phadia US Inc.$150Research paymentIn-kind items and servicesImmunoCAP Device, AllergyCABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population2020
2020-09-14Phadia US Inc.$300Research paymentIn-kind items and servicesImmunoCAP Device, AllergyCABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population2020
2020-09-01Phadia US Inc.$150Research paymentIn-kind items and servicesImmunoCAP Device, AllergyCABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population2020
2020-08-31Boehringer Ingelheim Pharma GmbH & Co.KG$2,033Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-08-31Boehringer Ingelheim Pharma GmbH & Co.KG$2,033Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-08-31Boehringer Ingelheim Pharma GmbH & Co.KG$1,799Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-08-26Covidien LP$167GrantIn-kind items and servicesNellcor Device, Pulse Oximetry2020
2020-08-21PFIZER INC.$2,253Research paymentIn-kind items and servicesZAVICEFTA NEONATAL SEPSIS TRIAL2020
2020-08-20Phadia US Inc.$150Research paymentIn-kind items and servicesImmunoCAP Device, AllergyCABAL 1718 The Microbiome, Asthma and Other Atopic Development in the Premature Population2020
2020-08-10Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$65Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$59Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$49Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$35Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$31Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$30Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$22Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$15Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$9Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$9Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$9Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$7Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$5Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-09Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-07-02Nabriva Therapeutics, plc$650Research paymentCash or cash equivalentA Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I2020
2020-05-29Merck Sharp & Dohme LLC$2,174Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-05-29Merck Sharp & Dohme LLC$458Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-05-29Merck Sharp & Dohme LLC$425Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-05-27PFIZER INC.$14,751Research paymentIn-kind items and servicesXALKORI Drug, ONCOLOGYFULL A PHASE III STUDY OF 131IMETAIODOBENZYLGUANIDINE 131IMIBG OR CRIZOTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNO2020
2020-05-27PFIZER INC.$14,751Research paymentIn-kind items and servicesXALKORI Drug, ONCOLOGYFULL A PHASE III STUDY OF 131IMETAIODOBENZYLGUANIDINE 131IMIBG OR CRIZOTINIB FOR TREATMENT OF CHILDREN WITH NEWLY DIAGNO2020
2020-05-26KARL STORZ Endoscopy-America$348GiftIn-kind items and servicesFORCEPS GRASPING 4FR 60CM Device, UROLOGY2020
2020-05-20Nabriva Therapeutics, plc$4,290Research paymentCash or cash equivalentA Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I2020
2020-05-08Incyte Corporation$60Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$45Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$45Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$35Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$35Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$35Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$31Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$23Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$4Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$3Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-05-08Incyte Corporation$1Research paymentCash or cash equivalentAn Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis2020
2020-04-15Eli Lilly and Company$11Research paymentIn-kind items and servicesTRULICITY Drug, DiabetesA RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACE2020
2020-04-02Hikma Pharmaceuticals USA$318Food and BeverageIn-kind items and services2020
2020-04-01PFIZER INC.$8,000Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESTHE UNITED STATES PEDIATRIC MULTICENTER PNEUMOCOCCAL SURVEILLANCE2020
2020-03-31Boehringer Ingelheim Pharma GmbH & Co.KG$2,033Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-03-31Boehringer Ingelheim Pharma GmbH & Co.KG$2,033Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-03-31Boehringer Ingelheim Pharma GmbH & Co.KG$1,799Research paymentIn-kind items and servicesTRADJENTA Drug, DIABETES52 wks Eff. & Saf. Ph III in Paediatrics2020
2020-03-31Nabriva Therapeutics, plc$650Research paymentCash or cash equivalentA Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I2020
2020-03-24Merck Sharp & Dohme LLC$28Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P2020
2020-03-12Cochlear Americas$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentNucleus Device, Implantable hearing solution2020
2020-03-12Cochlear Americas$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentNucleus Device, Implantable hearing solution2020
2020-03-09Incyte Corporation$24Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-03-09Incyte Corporation$21Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-03-09Incyte Corporation$12Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-03-09Incyte Corporation$12Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-03-09Incyte Corporation$10Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-03-05Insulet Corporation$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2020
2020-02-28Nabriva Therapeutics, plc$2,600Research paymentCash or cash equivalentA Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for I2020
2020-02-27PFIZER INC.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentEUCRISA Drug, DERMATOLOGY2020
2020-02-10DERMIRA, INC.$15,250Consulting FeeCash or cash equivalentQBREXZA Drug, DERMATOLOGY2020
2020-01-03Eli Lilly and Company$554Research paymentIn-kind items and servicesA PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREAT2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Diego CountySan Diego city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Diego, CA, county San Diego County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Diego, CA
County
San Diego County, CA
State
California
Population B010031,389,5263,288,77439,287,377
Population, 2020 census P11,386,9323,298,63439,538,223
Median age B0100236.237.337.9
Under 18 B0100118.4%20.9%22.0%
65 and over B0100114.6%15.4%15.7%
Households B11001530,4121,171,27813,548,091
Foreign born B0500225.1%22.8%27.0%
Median household income B19013$108,077$106,268$99,122
Median family income B19113$128,006$122,377$113,346
Per capita income B19301$57,083$51,976$49,513
Poverty rate B1700111.0%10.3%12.0%
Unemployment rate B230256.0%6.1%6.6%
Civilian labor force B23025755,8931,689,38420,068,466
Mean commute (minutes) B0801323.525.528.7
Bachelor's degree or higher B1500351.0%43.2%37.1%
Housing units B25001568,6681,250,64114,644,735
Owner-occupied B2500347.3%54.6%55.9%
Renters B2500352.7%45.4%44.1%
Median home value B25077$906,700$854,700$734,700
Median gross rent B25064$2,313$2,246$2,036
White, not Hispanic B0300240.9%42.4%33.8%
Black B030025.3%4.4%5.2%
Hispanic or Latino B0300229.8%34.6%40.2%
Asian B0300217.3%12.1%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Diego, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.